Dr. Y. Fred Yang serves as the Chief Development Officer at KBP Biosciences, where he plays a pivotal role in steering the company's flagship product development and securing a significant billion-dollar deal. With nearly 30 years of expertise in clinical research and drug development, Dr. Yang is recognized as a versatile biostatistician and innovative trialist. His leadership extends to overseeing regulatory affairs across multiple jurisdictions, managing medical affairs and KOL networks, ensuring compliance, and contributing to discovery and translational science. In 2023, Dr. Yang orchestrated the successful $1.3 billion asset deal for KBP's leading product, Ocedurenone, with Novo Nordisk. Dr. Yang obtained his undergraduate education from Peking University and earned his Ph.D. from the University of Wisconsin-Madison, and he also holds the position of Adjunct Associate Professor at Drexel University Medical School.